{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": -14.903848, "regularMarketPrice": 0.177, "exchange": "FRA", "shortName": "GENOR BIOPHARMA DL-,00002", "longName": "Genor Biopharma Holdings Limited", "messageBoardId": "finmb_625922050", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": -0.031000003, "regularMarketTime": 1683899145, "regularMarketDayHigh": 0.177, "regularMarketDayRange": "0.176 - 0.177", "regularMarketDayLow": 0.176, "regularMarketVolume": 1112, "regularMarketPreviousClose": 0.208, "bid": 0.0, "ask": 0.0, "fullExchangeName": "Frankfurt", "financialCurrency": "CNY", "regularMarketOpen": 0.176, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.0069999993, "fiftyTwoWeekLowChangePercent": 0.041176464, "fiftyTwoWeekRange": "0.17 - 0.53", "fiftyTwoWeekHighChange": -0.353, "fiftyTwoWeekHighChangePercent": -0.66603774, "fiftyTwoWeekLow": 0.17, "fiftyTwoWeekHigh": 0.53, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.19, "sharesOutstanding": 505772000, "bookValue": 3.539, "fiftyDayAverage": 0.2257, "fiftyDayAverageChange": -0.048700005, "fiftyDayAverageChangePercent": -0.21577317, "twoHundredDayAverage": 0.264665, "twoHundredDayAverageChange": -0.08766501, "twoHundredDayAverageChangePercent": -0.33123007, "marketCap": 110006912, "priceToBook": 0.050014127, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1602568800000, "priceHint": 4, "symbol": "67N0.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building 3", "address2": "1690 Zhangheng Road Pudong New District", "city": "Shanghai", "zip": "201203", "country": "China", "phone": "86 21 6169 0700", "website": "https://www.genorbio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.", "fullTimeEmployees": 264, "companyOfficers": [{"maxAge": 1, "name": "Dr. Feng  Guo Ph.D.", "age": 52, "title": "CEO & Chairman", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chengyi  Weng", "title": "VP of Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Qibin  Liang", "age": 65, "title": "Chief Technology Officer", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Shuhua  Han Ph.D.", "age": 63, "title": "Chief Scientist", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Xiaojing  Zhu", "title": "VP of Compliance & Admin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Tong  Li", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Cheery  Chen", "title": "Chief Regulatory Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Tak Wai  Ip", "title": "Company Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jun  Lin", "age": 37, "title": "VP of Quality Analysis", "yearBorn": 1985, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Qingtang  Duan", "age": 39, "title": "Gen. Mang. of Yuxi Genor", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}